HPV self-sampling improves cervical cancer screening accessibility, offering comfort, privacy, and early detection for ...
A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...
PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.
For patients with HPV16-positive CIN3, vaccination with a replication-incompetent Semliki Forest virus vaccine encoding HPV16 E6 and E7 is safe and shows clinical effectiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback